Compile Ke Ke
Recently, foreign media reported that the National Institute of Health Care Excellence (NICE) recommended AstraZeneca/Mersk’s Lynparza (Olabarib) and Roche’s Avastin (bevacizumab) through the Cancer Drug Fund (CDF).
), used for maintenance treatment of patients with homologous recombination defect (HRD) positive advanced ovarian, fallopian tube and peritoneal cancer that fully or partially respond to first-line platinum-based chemotherapy and bevacizumab.
This recommendation is based on data from the phase 3 clinical study PAOLA-1.
Compared with bevacizumab alone, olaparib combined with bevacizumab can reduce the risk of disease progression or death by 67%.
The combination of olaparib and bevacizumab also increased the patient's progression-free survival (PFS) from 17.
7 months to 37.
In this study, about 48% of patients were newly diagnosed patients with HRD-positive advanced ovarian cancer.
The British National Health System (NHS) supports the introduction of olaparib combined with bevacizumab therapy, and the organization is providing genomic HRD testing for patients who use the therapy for the first time.
This test only examines a tumor sample to determine the HRD and somatic BRCA mutation status.
Olabarib is known as a PARP inhibitor as an inhibitor of poly ADP ribose polymerase (PARP).
BRCA1/2 mutations may be genetically prone to cause certain cancers, and may also be resistant to other cancer treatments.
However, these cancers sometimes have a unique vulnerability because cancer cells increasingly rely on PARP to repair their DNA so that they can continue to divide.
This means that if the cancer is susceptible to this treatment, drugs that selectively inhibit PARP may be beneficial.
In December 2014, the European Medicines Agency (EMA) and the U.
Food and Drug Administration (FDA) approved olaparib as a single drug.
The US FDA approved the drug for use in advanced ovarian cancer with germline BRCA mutation (gBRCAm) that has received three or more chemotherapies.
In January 2018, olaparib became the first PARP inhibitor approved by the US FDA for gBRCAm metastatic breast cancer.
The drug was developed by the British biotechnology company KuDOS Pharmaceuticals and was first applied to patients.
Since KuDOS was acquired by AstraZeneca in 2006, AstraZeneca and Merck have carried out clinical development of the drug.
Olapali combined with temozolomide for relapse Small cell lung cancer has significant clinical activity.
NICE approves Lynparza plus Avastin via Cancer Drugs Fund